[Impact of stopping reimbursement of olmesartan for hypertensive patients in primary care].

CONCLUSIONS: Stopping olmesartan reimbursement didn't seem to have a significant impact on blood pressure control of hypertensive patients while its cost is significant. In addition to potential serious side effects, olmesartan has not shown any improvement in cardiovascular morbi-mortality.
PMID: 32312474 [PubMed - as supplied by publisher]

Source: Annales de Cardiologie et d'Angeiologie - April 16, 2020 Category: Cardiology Authors: Humbert X, Rabiaza A, Schonbrodt L, Raginel T, Le Bas F Tags: Ann Cardiol Angeiol (Paris) Source Type: research